Home / Industry Reports / Therapeutic Area Market Research
Sort By: Title Date Price

Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth

GBI Research, the leading business intelligence provider, has released its latest research: ‘Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth’, which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary

$4995 Read More

Global Radiation Therapy Market Report: 2015 Edition

Radiotherapy is a treatment procedure that involves the use of high-energy radiation. It is commonly applied to the cancerous tumor because of its ability to control cell growth and is also used to treat benign (non-cancerous) tumors and other conditions like thyroid disease and some blood disorders. Almost half of the cancer patients are being treated by radiation therapy. Nowadays, new treatment techniques such as image guided radiation therapy (IGRT), proton therapy; brachytherapy and stereotactic radiation therapy are being increasingly adopted. Moreover, due to the less risk in proton therapy treatment, it has become the most preferred option for treating cancer.

Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors

Competitor Analysis: Therapeutic Antibodies 2015: Biosimilars & Biosuperiors This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of April 2015. Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 82.2 bln (+8.6% vs previous year) in the year 2014.

$1500 Read More

Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants

This report provides an update of recombinant coagulation factors used for controlling bleeding of hemophilia A and B and other bleeding disorders. 2013 sales figures and 2014 nine-month sales data are analyzed to evaluate commercial development of the market under the light of a strong pipeline and entry of new competitor products into the market. The profiles of drug candidates in development are presented in details not only for recombinant coagulation factors VIII, IX and VII, but also for emerging alternative procoagulants, gene therapeutics and immune tolerance inducing agents.

$2795 Read More

Peptide Therapeutics Pipeline Database: 1-Year Subscription

Subscription to La Merie Publishing’s proprietary Peptide Therapeutics Pipeline Database provides online access to Peptide Therapeutics on the market and in research & development. The peptide segment database contains about 900 files. Each project (file) is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic peptides is intuitive. Data sets of interest can be printed and exported in Word or Excel format. Projects are being updated continuously by passive and active searches. Information from press releases is entered on a daily basis.

$1016 Read More

Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders

This business report from July 2014 is based on the identification, description and assessment of all relevant stakeholders in the field of botulinum neurotoxins. The report analyzes the existing product portfolios in regulated and less regulated markets, commercial information, and measures to maintain sales and market shares by upside indications and life cycle management measures. The report addresses the new wave of botulinum neurotoxin product candidates in development, such as biosimilars and biosuperior botulinum neurotoxins.

$2656 Read More

Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014

Biosimilar and Biosuperior Therapeutic Antibodies 2014 The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014 provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of March 2014. Marketed antibodies are attractive for companies to create next generation variants and  biosimilar copies because they represent clinically and commercially validated products.

$1523 Read More

Gastrointestinal Deals and Alliances of 2014

The Gastrointestinal Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.

$1495 Read More

Central Nervous System Deals and Alliances of 2014

The Central Nervous System Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014.

$1495 Read More

Motor Neurone Disease Partnering 2010-2015

The report provides an analysis of motor neurone partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors motor neurone technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Motor Neurone Disease Partnering 2015

The report provides an analysis of motor neurone partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors motor neurone technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis)

GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis)” by Kelly Scientific Publications is a comprehensive report on the cancer biomarker industry and its impact on the health system.

$3400 Read More

The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-2019)

The report titled “The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)” provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry.

US - Pain Management Therapeutics Patients & Market Analysis

Pain management is one of the fast growing medical disciplines that reduce chronic pain. Chronic pain afflicts a large population in the United States. The United States pain management therapeutics market has huge potential for growth due to the large population that is affected by medically significant pain.

$1100 Read More

US and Japan - Proton Therapy Market, Patients & Forecast

Proton therapy has become a subject of considerable interest in the radiation oncology community and it is expected that there will be a substantial growth in proton treatment facilities during the next decade. Proton therapy, one of the most intriguing developments in cancer treatment, carries a price tag as intimidating as its size. At a cost of US$ 125 Million, and sometimes much more, today’s centers usually fill a city block.

$1475 Read More

United States Gastroesophageal Reflux Disease Therapeutics Market Report 2017

In this report, the United States Gastroesophageal Reflux Disease Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

$3800 Read More

Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line

Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options.

$4995 Read More

Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth

Hepatitis B is an infectious liver disease caused by the Hepatitis B Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a significant number of migrants from medium and high-prevalence countries. 

$4995 Read More

Global Antifungal Agents Market Research Report 2017

In this report, the global Antifungal Agents market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

$2900 Read More

Global Checkpoint Inhibitors for Treating Cancer Sales Market Report 2017

In this report, the global Checkpoint Inhibitors for Treating Cancer market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

$4000 Read More

Global Anti-Cancer Injectable Sales Market Report 2017

In this report, the global Anti-Cancer Injectable market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

$4000 Read More

Global Nitric Oxide Therapy System Sales Market Report 2017

In this report, the global Nitric Oxide Therapy System market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

$4000 Read More

Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market

Breast cancer is a malignant neoplasm that begins in the breast tissue. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Broadly, patients can be segmented into two types: the human epidermal growth factor receptor (HER) 2-negative segment and the HER2-positive segment. HER2-positive breast cancer is aggressive and, historically, has had a worse overall survival than HER2-negative disease, which is considered less aggressive.

$4995 Read More

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability.

$4995 Read More

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases. This figure has been gradually rising with increased smoking and the growing elderly population. Lung cancer is a leading cause of death worldwide, accounting for 1.69 million deaths in 2015. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 a high-risk age range for lung cancer.

$4995 Read More

Dermatology Therapeutics Drug Development Pipeline Review, 2016

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established and generic products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.

$3995 Read More

Uveitis Therapeutics in Asia-Pacific Markets to 2023 – Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market

Uveitis refers to inflammation of the uvea, the middle vascular coat of the eye, comprising the iris, ciliary body, and choroid. It may also involve other adjacent tissues of the eye. Uveitis occurs at any age, but it most commonly affects individuals between 20 and 59 years of age. However, this trend is changing; the percentage of elderly uveitis patients has been increasing in recent years. Uveitis represents a major cause of ocular morbidity worldwide and often results in complications such as cataracts, glaucoma, ocular hypertension, macular issues, and retinal detachment.

$4995 Read More

Global Cardiovascular Disease Drugs Market to 2023 – Expiries, Acquisitions and New Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the Competitive Landscape

The cardiovascular disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia, which accelerate the development of atherosclerotic plaque build up within blood vessels. As atheroma develops it causes the affected blood vessels to narrow, restricting blood flow to the body, brain or heart, depending on its locale.

$4995 Read More

Global Genetic Disorders Drugs Market to 2023 – A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease

The genetic disorders therapy area consists of indications that arise because of an abnormality in a person’s DNA. This report focuses on the key therapy area indications of cystic fibrosis (CF), Duchenne muscular dystrophy (DMD), lysosomal storage disease (LSD) and paroxysmal nocturnal hemoglobinuria (PNH). Genetic disorders are frequently inherited from an individual’s parents but can also arise because of a new (de novo) mutation.

$4995 Read More

Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 – Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market

Head and neck cancer (HNC) is the sixth most common cancer, and its incidence is growing. The annual incidence of HNCs worldwide is more than 550,000 cases, with around 300,000 related deaths occurring each year. In terms of the initial site of development, 44% of HNCs involve the oral cavity, 31% the larynx and 25% the pharynx. The incidence of tobacco-related HNC is decreasing, but the incidence of cancer due to the human papillomavirus continues to increase at a rate of 2–4% per year. HNC is most common in the middle aged, with a peak incidence rate between the ages of 55 and 64, and a median age of diagnosis of 62.

$4995 Read More

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

Hemophilia is a rare disease affecting more than 400,000 people worldwide. Hemophilia A is four to six times as common as hemophilia B, and more than half of hemophilia A patients have a severe form of hemophilia. The mainstay of treatment for hemophilia is to replace the missing factor VIII or factor IX, produced using plasma-derived or recombinant methods.

$4995 Read More

Hepatitis C Therapeutics in Asia-Pacific Markets to 2023 – Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV), which can lead to acute and chronic hepatitis infection. According to the World Health Organization (WHO), in 2015 there were 1.75 million new HCV infections globally, and approximately 399,000 people die each year from hepatitis C, mostly due to cirrhosis and hepatocellular carcinoma.

$4995 Read More

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Colorectal Cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.4 million newly diagnosed CRC cases in 2012, accounting for 9.7% of the total number of cancer cases. This figure has been gradually rising in the Asia-Pacific region, with the growing elderly population and increasingly Westernized lifestyles.

$4995 Read More

Bladder and Ureter Cancer Drug Development Pipeline Review, 2017

This report provides an overview of the bladder and ureter pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for these two indications, and features dormant and discontinued projects.

$3995 Read More

Cancer Supportive Care Drug Development Pipeline Review, 2017

This report provides an overview of the Cancer Supportive Care pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cancer anorexia-cachexia syndrome, bone metastasis and cancer pain, and features dormant and discontinued projects.

$3995 Read More

Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017

This report provides an overview of the Gastric and Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for each of these cancer types, and features dormant and discontinued projects.

$3995 Read More

Sickle Cell Disease Drug Development Pipeline Review, 2017

This report provides an overview of the Sickle Cell Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for sickle cell anemia and vaso-occlusive crisis associated with sickle cell disease, and features dormant and discontinued projects.

$3995 Read More

Swine and Avian Influenza Drug Development Pipeline Review, 2017

This report provides an overview of the Swine and Avian Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A virus, subtypes H5N1 and H1N1, and features dormant and discontinued projects.

$3995 Read More

Colorectal Cancer Drug Development Pipeline Review, 2017

This report provides an overview of the colorectal cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for anal, rectal and colorectal cancer, and features dormant and discontinued projects.

$3995 Read More

Pneumonia Drug Development Pipeline Review, 2017

This report provides an overview of the pipeline landscape for pneumonia disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Community Acquired Pneumonia, Hospital Acquired Pneumonia and Ventilator Associated Pneumonia and features dormant and discontinued projects.

$3995 Read More

Genetic Ophthalmology Disorders Drug Development Pipeline Review, 2017

This report provides an overview of the pipeline landscape for genetic ophthalmological disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Stargardt disease, Leber congenital amaurosis, Leber’s hereditary optic neuropathy, Usher Syndrome and Retinitis pigmentosa, and features dormant and discontinued projects.

$3995 Read More

Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

This report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects.

$3995 Read More

Skeletal Disease Drug Development Pipeline Review, 2017

This report provides an overview of the skeletal disease pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for osteoporosis, post-menopausal osteoporosis and osteoarthritis (OA).

$3995 Read More

Transplantation Drug Development Pipeline Review, 2017

This report provides an overview of the transplantation pipeline landscape, specifically covering drugs used to prevent and treat organ rejection and graft-versus-host disease. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), and the rejection of bone, liver, kidney, lung and heart transplants.

$3995 Read More

Global Oncology Market to 2023 – Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis. These are generally incurable once they progress to the stage where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of all types, at various disease stages. In a typical course of therapy for cancer, multiple chemotherapy compounds are administered sequentially in combination regimens, as an adjunct to surgery and radiation therapy.

$4995 Read More

Global Immunology Drugs Market to 2022 –Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth

Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant autoimmune response against healthy tissues in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and mobility loss, and have a negative impact on quality of life.

$4995 Read More

CNS Cluster Addiction Drug Development Pipeline Review, 2017

The central nervous system (CNS) addiction cluster report provides an overview of the CNS Clusters pipeline landscape. The report provides comprehensive information on the therapeutics under development, and key players involved in therapeutic development for Alcohol Addiction, Drug Addiction, Nicotine Addiction, Opium (Opioid) Addiction and features dormant and discontinued projects.

$3995 Read More

Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017

This report provides an overview of the genetic disorders pipeline landscape, specifically focusing on muscular dystrophies. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Becker and Duchenne Muscular Dystrophy (BMD and DMD) and features dormant and discontinued projects.

$3995 Read More

Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017

This report provides an overview of the toxicology pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting, Chemotherapy Induced Neutropenia, Chemotherapy Induced Anemia, Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.

$3995 Read More

Women's Health Cluster Drug Development Pipeline Review, 2017

This report provides an overview of the women’s health pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for female infertility, polycystic ovarian syndrome and endometriosis, and also features dormant and discontinued projects.

$3995 Read More

Renal Cluster Drug Development Pipeline Review, 2017

This report provides an overview of the renal cluster pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Kidney Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Acute Renal Failure (ARF), Kidney Transplant Rejection, and also features dormant and discontinued projects.

$3995 Read More

Therapeutic Area Market Research Reports

A therapeutic area usually refers to a specific category of disease that has known medical treatments, drugs or other potential drug innovations. It is a process of categorizing medical drugs without referring to any kind of treatment or without taking a glance at the ailment that it treats. For example, cardiology can be considered in the therapeutic area. Likewise, other sections like urology, travel medicine, psychotherapy, dermatology and gynecological therapy can be bifurcated as therapeutic area also.

The worldwide treatment sector encompasses therapies that are designed to cure or handle particular ailments or diseases inside he internal system of the body. Nonetheless, the therapeutic area therapy and its consequent situations fluctuate in parallel and widely.

Representing digital/online leading market research reports from market experts , industry professionals and market analysts, Acute Market Reports is your unique /exceptional, investigative and comprehensive knowledge source for therapeutic area. The reason being that we source our market research reports from well established, branded and reputed publishers of the industry.

Our market reports fulfill your business requirements and fits your budget. It encompasses detailed information and analysis of market, market segments, market size, market edifice, market sections, business overview, company profile, market overview, competitive landscape, competive strategy, business strategy, product portfolio, benchmarking trends, technological trends, market growth factors, industry inhibitors, market share analysis, value chain analysis, micro environment of market, macro market environment , market attractiveness analysis, SWOT analysis, Strategic analysis, business process reengineering and environmental scanning represented through pictorial representation like graphs, diagrams, charts, excel sheets or spreadsheets and tables.